Efficacy should drive atypical antipsychotic treatment [7]

British Medical Journal

Volumn 326, Issue 7383, 2003, Pages 283-284

  Citrome, Leslie L ^a  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

DIABETES MELLITUS; DRUG EFFICACY; HUMAN; LETTER; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSIS; RISK FACTOR; RISK MANAGEMENT; TREATMENT OUTCOME;

AGE FACTORS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIABETES MELLITUS; HUMANS; PIRENZEPINE; RISK FACTORS;

EID: 0037309666     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (6)

1. Koro CE, Fedder DO. L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002;325:243-7.(3 August.)
2. Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension. Arch Gen Psychiatry 2001;58:1172-6.
3. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenbeck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-6.
4. Wang PS, Glynn RJ, Ganz DA, Schneeweiss S, Levin R, Avorn J. Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol 2002;22:236-3.
5. Kornegay CJ, Vasilakis-Scaramozza C, Jick H. Incident diabetes associated with antipsychotic use in the United Kingdom General Practice Research Database. J Clin Psychiatry 2002;63:758-62.
6. Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002;63:920-30.